Evidence map›Paper›PMID 42060162›Full record

ArticleAdvances in therapy2026

The Value and Impact of Weight Reduction from the Perspective of People in Canada with Type 2 Diabetes.

Melissa M Ross, Sarah Mulnick, Kristina S Boye, Jennifer Glass, Christine Longuet, Ashley Samuelson, Vivian Thuyanh Thieu, Michael Vallis, Meredith M Hoog

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Melissa M RossEvidera Inc., 929 North Front Street, Wilmington, NC, USA. Melissa.Ross@thermofisher.com.
Sarah MulnickEvidera Inc., 929 North Front Street, Wilmington, NC, USA.
Kristina S BoyeEli Lilly and Company, Indianapolis, IN, USA.
Jennifer GlassEli Lilly Canada, Toronto, Canada.
Christine LonguetEli Lilly Canada, Toronto, Canada.
Ashley SamuelsonEvidera Inc., 929 North Front Street, Wilmington, NC, USA.
Vivian Thuyanh ThieuEli Lilly and Company, Indianapolis, IN, USA.
Michael VallisFamily Medicine, Dalhousie University, Halifax, Canada.
Meredith M HoogEli Lilly and Company, Indianapolis, IN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionObesity and overweight are major contributing factors for type 2 diabetes (T2D). Here, we explored the perspectives of people with T2D on the value and expected impacts of reaching a lower weight.

methodsAdult residents of Canada with T2D completed a cross-sectional survey informed by qualitative interviews. Survey questions explored weight management experiences, T2D and weight impacts on quality of life, and the value of losing 5%, 10%, or 20% body weight. Results were summarized descriptively.

resultsOf 358 participants, 56% were male and 81% were white, with a mean age of 59 years (SD 13) and a mean self-reported body mass index of 32.9 kg/m

conclusionParticipants with T2D valued weight loss and anticipated improvements to their health and quality of life with greater perceived value and impacts associated with increased weight reductions.

Indexed as

Diabetes Mellitus, Type 2ObesityOverweightQuality of LifeWeight LossAdultAgedBody Mass IndexCanadaCross-Sectional StudiesFemaleHumansMaleMiddle AgedPsychological Well-BeingObesityOverweightPatient perceptionsQuality of lifeType 2 diabetesWeight reduction

Identifiers

PMID42060162
PMCPMC13290790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.